StockWatch
·
Biotechnology: Pharmaceutical Preparations
MergerNov 20, 2026, 04:26 PM

NextCure Sets Dec 8 Record Date for Merger CVR Distribution

AI Summary

NextCure, Inc. has announced the record and distribution dates for its pre-closing distribution of contingent value rights (CVRs) in connection with its previously disclosed merger agreement with Avere Therapeutics, Inc. The record date for the distribution is set for December 8, 2026, with the distribution expected to occur on December 14, 2026, contingent upon the first effective time of the merger. Each CVR will entitle holders to receive 90% of the gross proceeds from the sale, license, or disposition of NextCure's pre-merger legacy assets during the CVR term, after permitted deductions.

Key Highlights

  • NextCure's merger with Avere Therapeutics is proceeding, with a pre-closing distribution of Contingent Value Rights (CVRs).
  • The record date for the CVR distribution is December 8, 2026.
  • The CVR distribution date is expected to be December 14, 2026.
  • CVR holders will receive 90% of gross proceeds from the sale/licensing of pre-merger legacy assets.
  • Distribution is conditioned on the occurrence of the First Effective Time of the merger.